Regular
NAV (18-Jun-25)
Returns (Since Inception)
Fund Size
₹5,508 Cr
Expense Ratio
1.91%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+19.89%
+14.51% (Cat Avg.)
3 Years
+30.04%
+25.57% (Cat Avg.)
5 Years
+24.29%
+21.51% (Cat Avg.)
Since Inception
+21.55%
— (Cat Avg.)
Equity | ₹5,341.63 Cr | 96.99% |
Others | ₹165.89 Cr | 3.01% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹697.32 Cr | 12.66% |
Dr Reddy's Laboratories Ltd | Equity | ₹531.77 Cr | 9.66% |
Divi's Laboratories Ltd | Equity | ₹497.53 Cr | 9.03% |
Cipla Ltd | Equity | ₹432.13 Cr | 7.85% |
Aurobindo Pharma Ltd | Equity | ₹348.99 Cr | 6.34% |
Alkem Laboratories Ltd | Equity | ₹227.1 Cr | 4.12% |
Zydus Lifesciences Ltd | Equity | ₹220.95 Cr | 4.01% |
Lupin Ltd | Equity | ₹219.38 Cr | 3.98% |
Gland Pharma Ltd | Equity | ₹217.54 Cr | 3.95% |
Treps | Cash - Repurchase Agreement | ₹159.92 Cr | 2.90% |
Syngene International Ltd | Equity | ₹135.6 Cr | 2.46% |
Pfizer Ltd | Equity | ₹124.87 Cr | 2.27% |
Alembic Pharmaceuticals Ltd | Equity | ₹109.38 Cr | 1.99% |
Apollo Hospitals Enterprise Ltd | Equity | ₹98.79 Cr | 1.79% |
Medplus Health Services Ltd | Equity | ₹90.56 Cr | 1.64% |
Mankind Pharma Ltd | Equity | ₹89.13 Cr | 1.62% |
Biocon Ltd | Equity | ₹89.09 Cr | 1.62% |
Shilpa Medicare Ltd | Equity | ₹86.82 Cr | 1.58% |
Sagility India Ltd | Equity | ₹79.06 Cr | 1.44% |
Thyrocare Technologies Ltd | Equity | ₹78.48 Cr | 1.42% |
Advanced Enzyme Technologies Ltd | Equity | ₹78.3 Cr | 1.42% |
Windlas Biotech Ltd | Equity | ₹78.25 Cr | 1.42% |
Medi Assist Healthcare Services Ltd | Equity | ₹75.13 Cr | 1.36% |
Aarti Drugs Ltd | Equity | ₹70.57 Cr | 1.28% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹70.33 Cr | 1.28% |
Star Health and Allied Insurance Co Ltd | Equity | ₹70.02 Cr | 1.27% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹63.63 Cr | 1.16% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹58.76 Cr | 1.07% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹55.68 Cr | 1.01% |
Glenmark Pharmaceuticals Ltd | Equity | ₹55.2 Cr | 1.00% |
Aarti Industries Ltd | Equity | ₹54.18 Cr | 0.98% |
FDC Ltd | Equity | ₹52.57 Cr | 0.95% |
Procter & Gamble Health Ltd | Equity | ₹44.84 Cr | 0.81% |
AstraZeneca Pharma India Ltd | Equity | ₹43.86 Cr | 0.80% |
Emcure Pharmaceuticals Ltd | Equity | ₹39.58 Cr | 0.72% |
Senores Pharmaceuticals Ltd | Equity | ₹33.53 Cr | 0.61% |
Unichem Laboratories Ltd | Equity | ₹14.42 Cr | 0.26% |
Cash Margin - Derivatives | Other Assets And Liabilities | ₹8.41 Cr | 0.15% |
Laxmi Dental Ltd | Equity | ₹7.79 Cr | 0.14% |
Net Current Assets | Cash | ₹-2.43 Cr | 0.04% |
Laxmi Organic Industries Ltd | Equity | ₹0.53 Cr | 0.01% |
Large Cap Stocks
43.21%
Mid Cap Stocks
22.94%
Small Cap Stocks
30.70%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹5,068.28 Cr | 92.02% |
Basic Materials | ₹203.34 Cr | 3.69% |
Financial Services | ₹70.02 Cr | 1.27% |
Standard Deviation
This fund
15.65%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.24
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since May 2020
Since July 2022
ISIN | INF109KC1GE9 | Expense Ratio | 1.91% | Exit Load | 1.00% | Fund Size | ₹5,508 Cr | Age | 6 years 11 months | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
Total AUM
₹9,45,300 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk